We want to draw your attention to our latest article “Improving Quality Of Life For Patients With Osteoporosis Using MicroRNAs” Our simulations provide evidence for the utility of the osteomiR™ test for fracture risk assessment, and, furthermore, highlight the general potential of circulating microRNAs to be exploited as minimal-invasive diagnostic tools. Click here to read the study
We want to draw your attention to the latest publication in cooperation with TAmiRNA GmbH, in Obesity Surgery.” Reduction of Premature Aging Markers After Gastric Bypass Surgery in Morbidly Obese Patients.” The findings indicate a significant reduction of the proinflammatory SASP after bariatric surgery. An increase in telomere length and reduced oxidative stress at telomeres was observed. Moreover, miR10a-5p which is downregulated during aging was upregulated after surgery. Click here to read the study
We want to draw your attention to the latest publication of the VINFORCE research Group in cooperation with TAmiRNA GmbH, in Scientific Reports from Nature. “Bone-related circulating microRNAs miR-29b-3p, miR-550a-3p, and miR-324-3p and their association to bone microstructure and histomorphometry.” Scientific Reports, Volume 8,4867 (2018) MicroRNAs are promising new biomarkers for bone diseases. The findings enhance the potential value of circulating miRNAs as bone biomarkers and the clinical utility of miRNAs to reflect dynamic changes in bone formation and microstructure. Click here to read the study
TAmiRNA & Vivomicx have combined their technologies of laser microdissection and high sensitivity qPCR, which enables the quantitative analysis of cell-type specific RNA expression in complex tissues. Using this protocol TAmiRNA & Vivomicx have already been able to demonstrate: the profound difference of RNA expression between whole tumor and subsets of cells within the tumor and the large heterogeneity in RNA expression between colorectal* tumor compartments such as tumor, stroma and tumor endothelial cells. * Note: the technology can be utilized for almost any tissue sample. The combination of Vivomicx and TAmiRNA´s proprietary protocols is clearly superior to the current standard where only whole tumor material is analyzed, and marks another step on the road to make the [...]
